Cangrelor
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Cangrelor, sold under the brand name Kengreal among others, is a P2Y 12 inhibitor FDA approved as of June 2015 as an antiplatelet drug for intravenous application. Some P2Y 12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation. It is authorized as a generic medication.
Cangrelor, sold under the brand name Kengreal among others, is a P2Y 12 inhibitor FDA approved as of June 2015 as an antiplatelet drug for intravenous application. Some P2Y 12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation. It is authorized as a generic medication.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1329245666 under CC BY-SA 4.0; modifications have been made.